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Millennium Development Goal 5 addressed the need 
to improve maternal health by reducing the maternal 
mortality ratio by 75% and achieving universal access 
to reproductive health by 2015. This includes access 
to contraception.[1] The Saving Mothers 2008-2010: 
Fifth Report on the Confidential Enquiries into Maternal Deaths in 
South Africa (SA) quoted the institutional maternal mortality ratio 
to be 176.22/100 000 live births (4 867 deaths).[2] The top five causes 
for maternal mortality were non-pregnancy-related sepsis (mainly 
HIV-related), obstetric haemorrhage, complications of hypertension 
in pregnancy, pregnancy-related sepsis and medical and surgical 
disorders. A key preventive measure to reduce the lifetime probability 
of dying from pregnancy-related causes is to ensure access to family 
planning. 
According to the Population Reference Bureau, Family Planning 
Worldwide 2013, the lifetime risk of maternal death in SA is 1:140.[3] 
The use of modern methods of contraception in married women or 
women in union was 59.8%, with injectable contraceptive use being 
the most prevalent at 28.4%, sterilisation 15%, the pill 10.9%, and 
male condoms 4.3%, while intrauterine device (IUD) use was the 
least prevalent at 1%. The implant was not available in SA at the time.
National policy
The SA National Department of Health (DoH) launched the National 
Contraception and Fertility Planning Policy and Service Delivery 
Guidelines and National Contraception Clinical Guidelines in 2012. 
Five key action areas were identified:
• providing quality contraceptive health services
• stimulating community awareness
• placing integration into practice – integration of contraceptive and 
fertility-planning services into other health services
• strategic multisectoral collaboration
• evidence-guided planning and provision.[4]
Of importance is that the policy addresses the prevention and 
planning of a pregnancy, both of which need to be addressed within 
the context of HIV infection in SA. It also takes into account the needs 
of different groups of persons who may access the service, including 
adolescents, sex workers, lesbians, gay, bisexual, transgender and 
intersex persons, migrants, men, perimenopausal women and those 
with a disability or chronic condition.[5]
In the past, two methods have dominated contraceptive use in 
SA, i.e. the hormonal oral contraceptive and the progestogen-only 
injectable contraceptive, but there is currently a move towards an 
expanded method mix. This approach includes promotion of existing 
methods, while addressing underutilised methods, such as the IUD. 
There is also a phased introduction of other long-acting reversible 
contraceptives (LARCs) such as the single-rod implant. 
This government policy is closely aligned to the DoH frameworks 
and agreements for the National Service Delivery Agreement; the 
Millennium Development Goals 4, 5, 5b, and 6; the framework for 
sexual and reproductive health and rights; and the Campaign for 
Accelerated Reduction of Maternal Mortality in Africa.
Medical Eligibility Criteria
The Medical Eligibility Criteria (MEC) for use of contraception 
are published by the World Health Organization (WHO) as one of 
four evidence-based family planning guidelines.[6] The other three 
guidelines include selected practice recommendations for contraceptive 
use, the decision-making tool for family planning clients and providers 
and family planning (a global handbook for providers).
The WHO MEC aims to assist in accessing quality care in family 
planning by reviewing the MEC for selecting different methods 
of contraception. These criteria represent the latest clinical and 
epidemiological evidence available on the safety of various forms of 
contraception in specific medical conditions. The website is regularly 
updated when evidence changes.[6]
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One such occasion followed the findings of epidemiological studies 
on hormonal contraception and HIV acquisition, progression and 
transmission. The WHO convened a technical meeting in 2012 
to review the MEC for hormonal contraception and HIV. After 
deliberation of the evidence and analysis of the risk/benefit, it was 
decided that they would continue to recommend no restrictions on 
the use of hormonal contraception for women living with HIV or at 
high risk of HIV infection. However, they added a new clarification 
for women using the progestogen-only injectable contraceptive at 
high risk of HIV: ‘Some studies suggest that women using progestogen 
only injectable contraceptive may be at increased risk of HIV 
acquisition, other studies do not show this association … However, 
because of the inconclusive nature of the body of evidence on possible 
increased risk of HIV acquisition, women using progesterone only 
injectable contraception should be strongly advised to always use 
condoms, male or female, and other HIV preventive measures.’[6] 
Evidence for the use of  hormonal contraception, including the 
implant, for women using antiretroviral therapy is currently being 
reviewed again.
MEC is presented in table form and includes the medical condition, 
the type of contraceptive method and any clarification based on 
available evidence. It further divides method choice into initiation 
or continuation of treatment. A numerical grading system is used. 
Grade 1 indicates that the method is safe to use in a particular 
medical scenario, whereas Grade 4 indicates that the method is 
contraindicated. Grades 2 and 3 allow the prescriber to discuss the 
risks and benefits with the client.[6] 
Newer contraceptive methods –  
long-acting reversible contraceptives
LARCs are methods that require administration less than once per 
month. LARCs include the implant, intrauterine contraceptives 
(IUDs; the intrauterine system (IUS)) and injectable contraceptives. 
The advantage of LARCs is that the typical use equals the perfect 
use – which is similar to that of male and female sterilisation. The 
continuation rates of LARCs, as defined by the percentage of women 
continuing use at one year, remain high compared with other 
methods. Injectable contraceptives have for a long time been offered 
as a contraception choice in SA; therefore these will not be discussed 
further.
Implant
In SA, the Implanon NXT has been available since February 2014. 
Implanon NXT is a single-rod contraceptive implant measuring 
40 mm × 2 mm, containing 68 mg of etonogestrel and delivering a 
daily dose sufficient to suppress ovulation over a 3-year period.   
The percentage of women experiencing unintended pregnancy 
within the first year of use was the same for perfect and typical 
use at 0.05%.[7] Eighty-four per cent of women continued use at 1 
year, with the majority discontinuing treatment owing to bleeding 
abnormalities. Contraindications to the use of Implanon NXT 
include active venous thromboembolic disease, i.e. while a woman 
is on treatment for thrombosis, known or suspected sex steroid-
sensitive malignancies, history of severe hepatic disease as long as 
liver function values have not returned to normal, undiagnosed 
vaginal bleeding or a known hypersensitivity to the active substance 
or any part of the excipients of Implanon NXT. 
While no pregnancies were reported in study populations, in 
clinical practice pregnancies were related to insertion issues, making 
timing of insertion a critical step.[8] Pregnancy should be excluded if 
Implanon NXT has not been inserted at a safe time in the menstrual 
cycle. If no contraceptive method was used previously, insertion 
should be during days 1 - 5 of the cycle. If the woman was previously 
on a combined hormonal method including the pill, patch or ring, 
Implanon NXT should be inserted during the hormone-free week, but 
it may be inserted at any time if the woman is using a progesterone-
only contraceptive. When using the injectable contraceptive or IUS, 
Implanon NXT is inserted when the next injected dose or device 
insertion is due. Alternatively, women may be informed that the onset 
of action of the implant is 7 days after insertion and that they must 
therefore use additional protection or continue using their existing 
method for 7 days.
The main issue with Implanon NXT is the change in bleeding 
patterns;[9] this side-effect is responsible for women discontinuing use 
if they were not adequately counselled. The healthcare practitioner 
(HCP) should advise the woman that she may experience changes 
in the frequency, intensity and duration of menstrual bleeding. The 
bleeding pattern experienced in the first 3 months of use is usually 
indicative of the future bleeding pattern. Roughly 1 in 3 women 
continue with their normal menstruation, 25% will have 3 - 4 
bleeds in a year, 20% will experience amenorrhoea and 1 in 6 will 
have nuisance bleeds. The suggested management for troublesome 
bleeding includes 2 - 3 cycles of combined oral contraceptive pills 
(including the placebos) and non-steroidal anti-inflammatory drugs.
Implanon NXT does not affect haemostasis or the serum lipid 
profile and results in mild insulin resistance. There have been 
concerns regarding bone mineral density and the prolonged use of 
progestogens. However, although the implant suppresses ovulation, 
oestradiol concentrations remain at levels noted in the early to mid-
follicular phase.
Of clinical importance is that Implanon NXT is safe for use in 
obese and hypertensive women. It has the same MEC grading as 
the injectable contraceptive for use in postpartum and breastfeeding 
women and has a safer grading than the injectables for use in 
nulliparous women and adolescents.
Following removal of an Implanon NXT rod the etonogestrel levels 
are undetectable after a mean of 6 days (range 1 - 10 days), with 
reported return of ovulation within 3 weeks.[10]
Intrauterine contraception
The IUD and levonorgestrel IUS are both available in SA and 
the former may also be used as an emergency contraceptive. The 
percentage of women experiencing an unintended pregnancy in the 
first year of use is the same for typical and perfect use for these two 
forms of contraceptives, with similar continuation rates at 1 year: 78% 
and 80% for IUD and IUS, respectively.[12]
As previously noted, intrauterine contraception (IUC), including 
IUD and IUS, is underutilised in SA, which may be due to factors 
attributable to the healthcare system, the HCP or the end user. 
Common misperceptions held by the HCP surrounding the use of 
IUC in nulliparous women include: difficulty with insertion, pain 
and discomfort during and after insertion, higher risk of uterine 
perforation and expulsion, and the assumption that nulliparous 
women would not want an IUC although the evidence suggests 
otherwise.[11-14] Patients also have misconceptions about IUC, mainly 
related to the presence of a foreign body. These as well as the use of 
IUC in HIV-positive patients are being addressed in large studies and 
promoted extensively in contraception and fertility planning training. 
The IUS is marketed as Mirena® in SA and is a hormonal 
intrauterine system that provides contraceptive protection for up 
to 5 years. It comprises a T-shaped plastic frame with a cylindrical-
shaped reservoir containing 52  mg of levonorgestrel, released at a 
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rate of 20 μg daily. Its action is based on its local effect and includes 
thickening of cervical mucus, disruption of normal function and 
movement of sperm inside the uterus and fallopian tubes, reduction 
in endometrial growth and a weak foreign body reaction. Ovarian 
function is altered only during the initial months. After the first year 
of use ovulation rates are similar to those in copper IUD (CuIUD) 
users.
The CuIUD consists of a small flexible frame with copper sleeves 
or wire around it. The copper ions released from the IUD lead 
to an inflammatory response in the uterus and are also toxic to 
spermatozoa and embryos.
The newest LARC registered for use in the UK and USA is the 
lower-dose levonorgestrel IUS. It is licensed for 3 years, only used as 
a contraceptive and contains 13.5 mg of levonorgestrel, with a release 
rate of 12 μg daily. The lower-dose levonorgestrel IUS is smaller than 
that of the Mirena® and the inserter measures 3.80 mm in diameter, 
making it easier to insert, and it has fewer side-effects than the latter. 
The addition of this LARC serves to widen the array of contraceptive 
choices available to women.
Women should be encouraged to discuss their fertility plans at 
clinical consultations, which should follow an integrated clinical 
approach. All HCPs should have knowledge of contraception. This 
opportunistic approach may introduce the woman to a variety of 
contraceptive options, remembering that she may have other issues 
related to fertility intentions. If necessary, preconception counselling 
may be offered. There is also a tendency to feminise contraception 
based on the perception that it is a woman’s issue and responsibility, 
but wherever possible both partners should be involved.
Counselling provided by an expert caring for a woman with a 
complex medical or surgical condition emphasises the importance 
of contraception and fertility planning and gives the woman 
confidence that the contraceptive advice will not conflict with the 
treatment of her condition. Compliance and service quality require 
adequate counselling by appropriately trained staff with adequate 
and appropriate equipment and supplies. Counselling must include 
information regarding effectiveness of the various methods available, 
their mode of action, correct use, potential side-effects, health risks 
and benefits. Women should also be given information on symptoms 
that necessitate return to the clinic. Return to fertility following 
discontinuation of use must be discussed as well as information 
regarding sexually transmitted infections.
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